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Available online 13 December 2011Abstract The recent introduction of technologies capable of reprogramming human somatic cells into induced pluripotent
stem (iPS) cells offers a unique opportunity to study many aspects of neurodegenerative diseases in vitro that could ultimately
lead to novel drug development and testing. Here, we report for the first time that human dermal fibroblasts from a patient
with relapsing-remitting Multiple Sclerosis (MS) were reprogrammed to pluripotency by retroviral transduction using defined
factors (OCT4, SOX2, KLF4, and c-MYC). The MSiPS cell lines resembled human embryonic stem (hES) cell-like colonies in mor-
phology and gene expression and exhibited silencing of the retroviral transgenes after four passages. MSiPS cells formed em-
bryoid bodies that expressed markers of all three germ layers by immunostaining and Reverse Transcriptase (RT)-PCR. The
injection of undifferentiated iPS cell colonies into immunodeficient mice formed teratomas, thereby demonstrating pluripo-
tency. The MSiPS cells were successfully differentiated into mature astrocytes, oligodendrocytes and neurons with normal kar-
yotypes. Although MSiPS-derived neurons displayed some differences in their electrophysiological characteristics as compared
to the control cell line, they exhibit properties of functional neurons, with robust resting membrane potentials, large fast
tetrodotoxin-sensitive action potentials and voltage-gated sodium currents. This study provides for the first time proof of con-
cept that disease cell lines derived from skin cells obtained from an MS patient can be generated and successfully differenti-
ated into mature neural lineages. This represents an important step in a novel approach for the study of MS pathophysiology
and potential drug discovery.
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Multiple Sclerosis (MS) is the most common cause of non-
traumatic neurological disability among young adults
throughout the world. While the cause of MS is unknown,
this disease has traditionally been classified as an autoim-
mune inflammatory disease of the white matter. In recent
years much research has focused on the chronic neurodegen-
erative processes affecting the gray matter (Lassmann,
2010). MS patients have a genetic predisposition that is sub-
sequently triggered by one or more environmental factors
such as vitamin D deficiency or viral infection. Once the dis-
ease is initiated, it can result in self-limiting attacks of in-
flammatory infiltrations into the CNS ranging from several
per year to one every 10 years. In others, the course is slowly
progressive over many years. Treatment with medications
such as interferon β is only effective in some patients
(Killestein and Polman, 2011). There are currently no reli-
able surrogate markers to predict disease severity, type or
response to treatment. Despite the large resources now
invested in MS research, there are clearly a number of signif-
icant questions regarding pathogenesis, disease subtypes
and response to therapy that still need to be examined. Cur-
rently, analyses of MS samples have been limited to periph-
eral blood, DNA, cerebrospinal fluid, and either small
biopsy samples or autopsy tissue from MS patients
(Baranzini et al., 1999; Dutta and Trapp, 2011; Menon et
al., 2011). Brain biopsies are rarely obtained from typical
MS patients as this material is often not representative of
chronic ‘end-stage’ MS. Not surprisingly, much research has
relied on varieties of autoimmune-mediated demyelinating
models for an insight into its pathophysiology. Despite their
similarities with MS and benefits in understanding the dis-
ease, these models are different to the human disease
which has led to ineffective and even detrimental MS treat-
ments (Wekerle, 2008). The production of diseased-cell lines
from individuals with MS could provide exciting new oppor-
tunities for MS researchers and clinicians to study relevant
human cell types, including those from the CNS, and may po-
tentially shed further insight into the pathogenesis of this se-
verely debilitating disease.
Recently the direct reprogramming of somatic cells
through the induced expression of four transcription factors
(OCT3/4, SOX2, KLF4 and c-MYC) to produce induced pluripo-
tent stem (iPS) cells has proved to be a major advance in stem
cell biology (Takahashi and Yamanaka, 2006; Nishikawa et al.,
2008), attracting considerable worldwide attention in disease
modeling, drug screening and regenerative medicine (Ebert et
al., 2009). iPS cells derived from adult somatic cells such as fi-
broblasts are able to differentiate into cell types representing
all three embryonic germ layers — essentially any cell in the
body. This technology could enable the generation and de-
tailed examination of oligodendrocytes, astrocytes and neu-
rons in the laboratory to study MS. Moreover, such diseased
cell lines would also be invaluable for testing new drug treat-
ments on the patient's own cells.
Although there is much expectation and speculation that
in the future iPS cells could be used to repair damaged or-
gans including the CNS, a more immediate and important
role is the large scale production of relevant cells carrying
the genetic susceptibility from the MS patient and subse-
quent analysis of these cells under controlled conditions inthe laboratory. Here, we report as proof of concept, the suc-
cessful derivation of iPS cell lines from a skin biopsy of an MS
patient and their differentiation into the three main CNS
neural lineages, astrocytes, oligodendrocytes and neurons.
Results
Derivation of MSiPS cells from skin fibroblasts
Primary skin cells migrated out from the skin tissue after
14 days and exhibited typical fibroblast morphology. These
human dermal fibroblasts (HDF) were used to derive MSiPS
cell lines through the induced expression of the four tran-
scription factors OCT3/4, SOX2, KLF4 and c-MYC. After one
reprogramming event, 0.6×104 transduced patient fibro-
blasts were seeded in 6 well plates. After 12 days, 25–40 dis-
tinct colonies were observed in each well, exhibiting
morphology similar to ES and iPS cell colonies (Fig. 1A;
clone 12, passage 10). At day 18, twenty colonies were pick-
ed and mechanically dissociated for replating and passaging.
Two of those were taken for characterization and differenti-
ation studies and were considered to be the “established
clones” (Takahashi et al., 2007). Of note, the addition of bu-
tyrate to transduced HDF cells on day 7, increased the yield
of MSiPS cell colonies generated, the efficiency of MSiPS der-
ivation being 0.24–0.67% compared with 0.033–0.066% in
absence of butyrate (Supplementary Fig. 1). Target vectors
were integrated in the genomic DNA of the MSiPS cell colo-
nies (passage 3) but not in the non-transduced HDF and
human embryonic stem cell line (H9) control cells
(Fig. 1G). qPCR performed with transgene-specific primers
6 days post-retroviral induction in HDF cells showed an up-
regulated expression of OCT3/4, SOX2, c-MYC and KLF4
transgenes (Fig. 1H). These genes were totally absent in
the MSiPS cell clones as well as the control H9 and original
HDF cells (Fig. 1H), indicating retroviral silencing. DNA ge-
netic fingerprinting confirmed that HDF and MSiPS cells
were genetically identical but have different alleles from
the control H9 (Table 1).
Characterization of MS-derived iPS cells
All colonies stained alkaline phosphatase-positive, a pheno-
typic characteristic of undifferentiated ES and iPS cells
(Fig. 1B). To confirm that the generated iPS cells had the char-
acteristics of typical human pluripotent embryonic stem cells
(hES), we further examined the expression of stem cell
markers on MSiPS cells (clone 6) by immunofluorescence. As
demonstrated in Figs. 1C–F, OCT3/4, TRA-1-60, SSEA-4 and
TRA-1-81 were expressed on all MSiPS cell colonies examined.
RT-PCR showed that the MSiPS cells also expressed the stem
cell marker genes for endogenous SOX2, reduced expression
protein 1 (REX1), telomerase reverse transcriptase (hTERT),
developmental pluripotency-associated (DPPA)-2, DPPA4,
DPPA5, and fibroblast growth factor (FGF)-4. The expression
pattern of these genes was comparable to that found in the
control hES cell line, H9 cells but was clearly absent in the
original starting HDF cells (Fig. 1I).
To further assess if epigenetic remodeling had occurred,
we interrogated the DNA methylation status at the promoter
region of OCT3/4 using EpiTYPER DNA methylation analysis,
Figure 1 Generation of iPS cells from MS patient fibroblasts following retroviral transduction. (A) Morphology of MSiPS cells (clone
12 passage 10) showing that they resembled that of human embryonic stem cells (H9) and are (B) alkaline phosphatase positive. Im-
munofluorescence staining of the MSiPS cell colonies shows the localization of the stem cell markers OCT3/4- (C), TRA-1-60-
(D), SSEA-4- (E), and TRA-1-81-proteins (green) (F), corresponding DAPI-stained nuclei (blue). Scale bar=500 μm for A; 250 μm for
B and 50 μm for C–F. (G) PCR of genomic DNA showing the integration of the target vectors SOX2, c-MYC, OCT3/4 and KLF4 in
MSiPS cells (clones 6 and 12) compared to the HDF and H9 cells. β-actin is shown as a loading control for positive amplification.
(H) qPCR confirming retroviral silencing in the MSiPS cell clones (passage 5) as evidenced by the loss of OCT3/4, SOX2, KLF4 and
c-MYC expression, analogous to H9 and HDF cells. Up-regulation of these genes was observed in HDF cells, 6 day after retroviral trans-
duction. (I) RT-PCR demonstrates that MSiPS cells and control H9 cells expressed high level of OCT3/4, SOX2, REX1, TERT, DPPA2,
DPPA4, DPPA5 and FGF4, as compared to the HDF parental cells.
261Generation of multiple sclerosis-specific neural cellswhich quantifies gene-specific CpG methylation. As shown in
Fig. 2A, methylation patterns of the two MSiPS cell clonal
lines examined (clones 6 and 12) were distinct from that of
the parental HDF cells but highly similar to the H9 control
cell line. The predominantly demethylated OCT3/4 promot-
er region of the MSiPS cell lines suggests that epigenetic
remodeling has indeed occurred during the reprogramming
process and that this promoter is active in the human plurip-
otent cells. Chromosomal analysis of the HDF cells using G-
banding revealed a normal female karyotype of 46XX in 20
cells (Fig. 2B).Further analysis of the MSiPS cells using whole genome
microarray demonstrated that MSiPS cells are highly similar,
although not identical, in their gene expression profile to
the H9 cells. This level of similarity between the MSiPS
cells and the H9 cells is consistent with previous reports of
reprogramming (Takahashi et al., 2007; Jia et al., 2010). Hi-
erarchical clustering of the triplicate samples of H9, MSiPS
and the HDF cells indicated that the MSiPS cells cluster
with the ES cells, forming a distinct branch to the HDF paren-
tal line (Fig. 2C, upper). Scatter plot analysis of the global
gene expression profile further demonstrated the similarity
Table 1 STR analyses of human dermal fibroblast (HDF)
derived MSiPS cells.
STR
marker
MSiPS MSiPS HDF H9
Clone 6 P3 Clone12 P3
D1S478 178, 180 178, 180 178, 180 160, 180
D3S1038 107, 215 107, 215 107, 215 107, 215
D5S346 171, 185 171, 185 171, 185 171, 171
D6S1024 122, 138 122, 138 122, 138 130, 138
D13S258 244, 274 244, 274 244, 274 228, 282
D18S535 483, 487 483, 487 483, 487 479, 487
D21S1413 154, 170 154, 170 154, 170 154, 178
AMEL 105 105 105 105
262 B. Song et al.between the MSiPS cells and the H9 cells (with a Pearson cor-
relation co-efficient of r2=0.93) and further highlighted the
differences between the MSiPS and parental HDF line, which
demonstrate a much lower level of correlation (r2=0.81,
Fig. 2C lower). The expression profile of the pluripotency as-
sociated genes SOX2, OCT3/4 and REX1 was at similar high
levels in both the MSiPS and H9 cells, but was not apprecia-
bly expressed in the HDF cells. Taken together, our analyses
of MSiPS cell colonies derived from retrovirally transduced
human cells confirm pluripotent potential.
Pluripotency potential of MSiPS cells
MSiPS cells were differentiated into embryoid bodies (EBs)
and assessed for gene expression using qPCR. As shown in
Figs. 3A–C, the stem cell markers SOX2, Nanog and REX1
were highly expressed on the original MSiPS cells (clones 6
and 12) in comparison to the day-7 differentiated EB clone
6 and EB clone 12. In contrast, EBs expressed high levels of
the three germ layer differentiation markers SMA (meso-
derm), AFP (endoderm) and NCAM (ectoderm), which were
absent in the undifferentiated iPS cells originating from the
same colonies (Figs. 3D–F). The pluripotency potential of
the MSiPS cells was further demonstrated in vivo, in immu-
nodeficient mice. The formation of encapsulated cystic ter-
atomas was observed in all recipient mice and showed
differentiated tissues from all three germ layers (Fig. 3G):
endoderm (serous glands); mesoderm (muscle and adipose
tissue) and ectoderm (neural tissue).
Neural differentiation of MSiPS
To confirm the neural differentiation potential of the MSiPS
cells, NSCs were generated using complete NS medium as
described in Materials and methods. Compared to MSiPS
cells and the control H9 cells, NSCs (passage 8) displayed a
profile suggestive of neural induction. Indeed, as shown by
RT-PCR, the expression of the stem cell markers OCT3/4,
TERT, REX1 and Nanog was present in MSiPS cells but not
detected in the NSCs or HDF cells. By contrast, the expres-
sion of the early neuroectoderm markers SOX1, NSE, dorsal
forebrain marker Pax6, neural stem cell markers Nestin
and Tuj1, the dendritic marker MAP2, the Ca2+-binding pro-
tein S100 and the astrocytic marker GFAP was observed at a
low level in NSCs D0 and increased significantly in thedifferentiated NSCs. The oligodendrocyte markers Oligo2
and PLP were also up-regulated (Fig. 4A). Immunofluores-
cence confirmed that the freshly plated NSCs expressed
the early neural stem cell markers, Nestin, RC2 and the oli-
godendrocyte precursor marker A2B5 (Figs. 4B–G), further
supporting the neural differential potential of MSiPS cells.
We next assessed if, with additional time in culture,
these NSCs could be differentiated into mature neurons, as-
trocytes and oligodendrocytes. Two weeks after adding the
complete NS medium (see Materials and methods) to the
NSCs D0, neurites grew out from the NSCs and began expres-
sing immature neural markers (Figs. 5A–C). As determined
by immunofluorescence, the number of DCX- and NF-200-
positive cells were 44.3±7.1% (n=154) and 43.7±12.3
(n=154), respectively.
Following an additional 2 weeks in culture neural networks
formed, with some cells adopting an astrocytic morphology.
Immunofluorescence staining showed that the differentiated
MSiPS cells comprised a mixed population of cells expressing
one or more of the following markers: GFAP, 50.5±11.0%
(n=846), βIII-tubulin, 72.7±7.3% (n=756) and MAP2 (mature
neuronalmarker), 56.9±3.2%, (n=591) (Figs. 5D–G). These re-
sults are in agreement with the PCR results obtained with the
differentiated NSCs (Fig. 4A, NSC-Diff). Furthermore, as illus-
trated in Fig. 4H, qPCR analysis showed that the neuronal sodi-
um channel markers, Nav1.1, Nav1.2, Nav1.3, Nav1.6 and
Nav1.7 are also expressed in the MSiPS-derived NSCs D0 and
in neurally differentiated MSiPS cells (NSC-diff). Little or no
expression of those sodium channel genes was observed in
the HDF, H9 and non-differentiated MSiPS cells. Under further
modified differentiation culture conditions, these NSCs dem-
onstrated an oligodendrocyte differentiation potential by
extending fine radial processes and displaying positive staining
for CNPase, MOG, MBP, O4 and MOSP (Figs. 6A–J and supple-
mentary Fig. 2A–L). The percentage of O4- and MBP-positive
cells in these oligodendrocyte-enriched cultures, were 47.2±
7.1% (n=39) and 88.9±5.4% (n=39), respectively.Electrophysiology
To further establish the phenotypic maturation of the MSiPS
cell derived neurons, we studied their electrophysiological
properties. For these studies we selected cells with a “neu-
ral appearance”, that is a compact cell body from which em-
anated 2–3 long, gracile projections that resembled axons or
dendrites in appearance (Figs. 7A, D). MSiPS-derived neural
cells had resting membrane potentials of −74±2 mV, mem-
brane capacitances of 21±2 pF, and input resistances of
1.0±0.1 GΩ (n=17) in current clamp. The cells were quies-
cent, that is, they did not fire action potentials spontane-
ously. However, robust action potentials could be elicited
by depolarizing current injection (Fig. 7B, red line). These
evoked action potentials had amplitudes of 90±7 mV
(n=17), width at half amplitude of 1.7±0.5 ms, and were
blocked by tetrodotoxin (TTX, 0.3 μM) (Fig. 7B, green line).
Only a single action potential occurred in response to a
depolarizing current step. In voltage clamp, step depolariza-
tion evoked an inward current that was activated at poten-
tials from −50 mV, had a maximum at −10 mV, and was
blocked by TTX (Fig. 7B, n=17). H9-derived neuronal cells
had significantly less negative resting membrane potentials
Figure 2 (A) Bisulfite genomic sequencing of OCT4 promotor showing demethylation in the 2 MSiPS lines (clones 6 and 12) compared
to the patient fibroblasts (HDF) and the H9 control cell line. Open circles indicates 0% methylation and black circles 100% methyla-
tion. (B) MSiPS cells (clone 6) were found to have a normal 46XX karyotype. (C, Upper) Average-linkage hierarchical clustering of
the normalized gene expression profiles of the replicate data (n=3) from the parental HDF cells, the reprogrammed MSiPS and the
control H9 cells, demonstrating the similarity between the two pluripotent cell lines. (Lower) Scatter plots of the global gene expres-
sion profile of the MSiPS cells compared to the H9 or HDF cells. Arrows indicate the position of the pluripotency-associated genes,
SOX2, OCT3/4 and REX1.
263Generation of multiple sclerosis-specific neural cells(−63±3 mV, n=5, P=0.013) and fired action potentials spon-
taneously (Fig. 7E). The characteristics of these action po-
tentials (seen on a faster time scale in Fig. 7B, blue line)and the current/voltage relationship for H9-derived neuro-
nal cells (Fig. 7F) were similar to those for MSiPS-derived
neuronal cells (Fig. 7C). Both the spontaneous action
Figure 3 (A–C) qPCR analysis showing that the stem cell markers SOX2, Nanog and REX1 are highly expressed on the original MSiPS
cells (clones 6 and 12) relative to the day-7 differentiated EBs. While the expression of the three germ layer differentiation markers,
SMA (mesoderm), AFP (endoderm) and NCAM (ectoderm) are up-regulated in the EBs, these are absent in the undifferentiated MSiPS
cells (D–F). (G) Teratoma formation following the injection of undifferentiated MSiPS cells into immunodeficient mice. Hematoxylin
and eosin staining showed evidence of tissues from all three germ layers including endoderm (serous glands); mesoderm (muscle and
adipose tissue) and ectoderm (neural tissue). Scale bar=100 μm for G.
264 B. Song et al.potentials (Fig. 7E) and the underlying current (Fig. 7F) were
blocked by TTX (0.3 μM).Discussion
In this study we present evidence for the first time that dif-
ferentiated oligodendrocytes, astrocytes and functional
neurons can be obtained by direct reprogramming of skin fi-
broblasts from a patient with MS, thus opening new avenues
for modeling this complex neurological disease. Consistent
with previous studies (Takahashi et al., 2007; Park et al.,Figure 4 (A) RT-PCR analysis performed on original fibroblasts (HD
ation (Diff) showing that the expression of the stem cell markers OCT
cells and H9 control cells as compared to HDF. Note that at D0, NSC
Pax6, Nestin, MAP2, S100 and Oligo2 After a further 4 weeks differ
Tuj1 were significantly up-regulated compared to the NSCs. (B–G)
from MSiPS cells. (B) nestin, green; (C) RC2, red; (D) Merge; (E) nes
(H) qPCR analysis performed on HDF, MS-iPS, NSCs Day 0, differentia
nal sodium channels Nav1.1, Nav1.2, Nav1.3, Nav1.6 and Nav1.7.2008; Song et al., 2011), the MSiPS cell line we have estab-
lished is similar to hES cells in many aspects including mor-
phology, proliferation, feeder dependence, surface
markers, gene expression, promoter activities, and terato-
ma formation. The minor differences in gene profiling and
electrophysiology fall within the variability of embryonic
cell lines from different sources and culture conditions
(Richards et al., 2004). Variability in neural differentiation
potential among pluripotent stem cell lines is well described
(Osafune et al., 2008; Chamberlain et al., 2010; Kim et al.,
2011). Similar differences are described in the efficiencies
by which human ES and iPS cells undergo specificationF), MSiPS cells, NSCs at day 0 (d0) and after 4 weeks differenti-
3/4, TERT, REX1 and Nanog were up-regulated in both the MSiPS
s (passage 8), began to express the neural markers, SOX1, NSE,
entiation (Diff), these neural markers including PLP, GFAP and
Expression of early neural progenitor markers on NSCs derived
tin, green; (F) A2B5, red. (G) Merge. Scale bar=50 μm for B–G.
ted NSCs (Diff) and H9 showing the relative expression of neuro-
265Generation of multiple sclerosis-specific neural cellsdown the neural lineages, although both can be directed to
form comparable neural progenitors. This suggests that
once specified to a neural fate, the pluripotent cells areequally efficient at generating neural cells (Kim et al.,
2011). In this context, it is noteworthy that a comprehensive
and detailed study by Hu et al. (2010) demonstrated clearly
Figure 5 Differentiation of MSiPS cells into three neural lineages. (A–C) Following 2 weeks differentiation of NSCs, neurite growth
was observed and the cells started expressing doublecortin (DCX; green) and neurofilament (NF-200; red) markers. (D–F) Following an
additional 2 weeks in culture, a neural network was formed with some cells adopting an astrocytic morphology demonstrating a mixed
population of cells expressing the astrocyte marker GFAP (D; green) and the neuronal marker βIII-tubulin (E; red), (F, red and green)
βIII-tubulin and GFAP and (G; green) mature neuronal marker MAP2. Scale bars=50 μm for A–D, G; 100 μm for E, F.
266 B. Song et al.that human iPS cells differentiate to neural lineages accord-
ing to the same temporal program as hESCs and can produce
functional neurons. However, the neural differentiation of
human iPS cells is not only variable between the different
iPS cell lines, but also unpredictable and much less efficient
than hES cells (Hu et al., 2010). Consequently, any cell-
based modeling using multiple iPS cell lines will need to
take into consideration the issue of appropriate controls.
With the current experimental paradigm, only a small por-
tion of human fibroblasts transduced with the four transcrip-
tion factors acquired iPS cell identity. From a practical point
of view, this efficiency is sufficiently high, since multiple iPS
cell clones could be obtained from a single transduction ex-
periment. Despite this limitation, we clearly show here that
it is possible to produce 3 different lineages of genetically-
matched neural cells from MS patient fibroblasts.
The generation of neural cells from patients with MS is an
important first step towards a new avenue of MS research.
Disease modeling using iPS-generated cells has already im-
proved understanding of a number of rare conditions includ-
ing spinal muscular atrophy (Ebert et al., 2009), Timothy
Syndrome (Yazawa et al., 2011) and familial dysautonomia
(Lee et al., 2009). These conditions all have relatively sim-
ple and known pathogenic genetic mutations. This is in con-
trast to MS, which involves a complex interaction between
genetic susceptibility and environmental exposure
(Oksenberg and Baranzini, 2010). Indeed, epidemiologicaldata suggest that genetic factors contribute significantly to
disease susceptibility in MS as well as disease course and
may explain much of the observed clinical and pathological
heterogeneity (Oksenberg and Baranzini, 2010). The MHC re-
gion is by far the most significant region contributing to this
disease, although an increasing number of non-MHC loci have
been identified in the last few years (Fugger et al., 2009).
These loci include genes involved in immune and neuronal
function (Saha and Jaenisch, 2009). The real challenge is to
prove a functional role for these genetic determinants, tak-
ing into account the complexity of gene regulation
(Lucchinetti et al., 2000). The generation of clinically rele-
vant models of MS that mimic the pathological heterogeneity
of the disease has proved difficult, and thus cells containing
the genetic fingerprint for MS may provide a useful model to
study this disease and give insights into its pathophysiology
and response to treatments (Lucchinetti et al., 2000; Saha
and Jaenisch, 2009). Indeed, the possibility of performing a
comprehensive transcriptional profile on neural differentiat-
ed iPS cells containing a genetic predisposition to MS, as well
as assessing the influence of epigenetic factors, could poten-
tially reveal a phenotype important to pathogenesis and
amenable to treatment. For example the functional effects
of MS associated genes such as the IL7R, which is differen-
tially expressed in primary progressive MS compared with re-
lapsing or secondary progressive patients (Booth et al.,
2005), could be examined in differentiated iPS cells from
Figure 6 (A–I) Under oligodendrocyte differentiation conditions, MSiPS cells demonstrated an oligodendrocyte phenotype con-
firmed by positive staining for CNPase (A; green), MOG (B; red), Merge (C), MBP, (D; green), O4 (E; red), Merge (F), MBP
(G; green), MOSP (H; red), Merge (I). Representative phase contrast of oligodendrocytes culture (J). Scale bar=50 μm for A–I,
100 μm for J.
267Generation of multiple sclerosis-specific neural cellspatients with different forms of MS. The generation of MS
patient-derived iPS cells also offers the possibility to study
other potentially important aspects of MS pathogenesis,
such as those contributing to the neurodegenerative pro-
cess. These could include the examination of the role of mi-
tochondrial failures (Su et al., 2009) and/or the potential of
widespread DNA deletions in neurons, as well as the effect of
the amiloride sensitive cation channel 1 (also known as ASIC
2) gene on axonal damage and loss (Bernardinelli et al.,
2007; Friese et al., 2007).
Neurons differentiated from stem cells and iPS cell-
derived neurons have previously been characterized electro-
physiologically (Kim et al., 2011). Electrical signaling is crit-
ical to neuronal function and thus regulation of ion channels
in neurons and transmitter receptors are important determi-
nants of appropriate function. Accordingly, the neural cells
differentiated from MS fibroblasts were tested electrophysi-
ologically and displayed characteristics of functional neu-
rons. Their resting membrane potentials were robust andthe amplitude of action potential large. These data are con-
sistent with the characteristics of mature neurons. However,
synaptic activity did not occur in these cells and this could
be the result of the paucity of astrocytes which are neces-
sary for synaptic development (Christopherson et al., 2005;
Hu et al., 2007; Johnson et al., 2007). Alternatively, there
could be differences in potassium, cation or chloride chan-
nels. Given that the value of the resting membrane potential
is determined by the type, relative density and distribution
of ion channels, it will be of interest in further studies to as-
sess whether these variables are altered in response to de-
myelination (Waxman, 2006a; Krishnan et al., 2009). In
contrast, H9-derived neurons fired action potentials sponta-
neously, with each action potential triggered by a spontane-
ous depolarization of around 10 mV, clearly visible in the
lead up to the spontaneous action potential and in the pres-
ence of TTX (Fig. 7).
Giant depolarizing potentials have been described in hip-
pocampal neurons (Ben-Ari et al., 1989) and may be
Figure 7 Electrophysiological characterization of MSiPS and control H9 cells. (A) MSiPS cells were quiescent but action potential
could be evoked by depolarizing current steps (red line). This evoked action potential was blocked by TTX 0.3 μM (green line).
(B) In voltage clamp depolarizing, voltage steps evoked an inward current in MSiPS cells that was blocked by TTX. (C) In contrast
to MSiPS cells, H9 cells fired spontaneous action potentials (see also blue line in (A)) and these were blocked by TTX, revealing spon-
taneous depolarizing potentials. (D) Depolarizing voltage steps evoked TTX sensitive inward currents in H9 cells.
268 B. Song et al.essential for neuronal development in the immature brain
(Cherubini and Ben-Ari, 2011). In neuronal cultures derived
from human fibroblasts from Angelman syndrome patients,
the presence of astrocytes was associated with the forma-
tion of functional synaptic contacts (Chamberlain et al.,
2010). However, a recent study indicated that astrocytes
may not be a necessity in the development of synapses in
ES cells 36 days after neural differentiation (Stroh et al.,
2011). In the present study, the rapid depolarizations re-
sponsible for the spontaneous action potentials were not
synaptic in nature, as they were not blocked by agents that
antagonize receptors for neurotransmitters. The differences
in some of the electrophysiological characteristics we ob-
served between MSiPS- and H9-derived neurons, namely
the absence of excitatory or inhibitory synaptic potentials
or currents in the MSiPS-originated cells, is of interest as
this suggests that the MSiPS-derived neurons may have
retained changes associated with the disease. We cannot
however, exclude the possibility that such differences re-
flect the origins of these two cell types. Additional experi-
ments are currently underway to further shed light on this
issue. Nonetheless, every MSiPS-derived neuron tested was
capable of sustaining an action potential upon depolariza-
tion, confirming that they are capable of functioning as neu-
rons. In this context it is interesting to note that the ionchannels Nav1.1, Nav1.2, Nav1.3 and to a lesser extent
Nav1.6 and Nav1.7 (Waxman, 2006b) are present on the
MSiPS-derived neurons as detected by qPCR, suggesting the
possible contribution of these ion channels to the action po-
tential activities of those cells.
Astrocytes have been revealed as important targets in the
pathogenesis of neuromyelitis optica (Sharma et al., 2010)
and primary astrocyte dysfunction could potentially contrib-
ute to MS pathology in a different subset of patients. Our abil-
ity to differentiate astrocytes from MSiPS cells provides a
further tool to unravel their role in the formation of chronic
and active MS lesions (Holley et al., 2003). Other glial cells
have also been implicated as playing a primary pathogenic
role in MS. Lucchinetti et al. (2000) described significant pri-
mary oligodendrocyte dysfunction/death in various subgroups
of MS (Pattern III and IV) that was supported and generalized
by Barnett and Prineas (2004). A few in vitro protocols have
been established to induce the differentiation of ES cells into
an oligodendrocytic cell lineage with variable efficiency and
stability (Barberi et al., 2003). More recently, attempts to dif-
ferentiate iPS into neural cell lineage have been described
(Hatch et al., 2009; Onorati et al., 2010). Here, we have opti-
mized these protocols and show that NSCs derived from MSiPS
cells can differentiate and maturate into myelin protein-
expressing oligodendrocytes in vitro.
269Generation of multiple sclerosis-specific neural cellsWhile there is great potential for iPS cells in diseasemodel-
ing and drug screening, there are also a number of challenges.
As indicated above, the careful selection of controls, including
normal iPS cell lines, need to be generated from either close
relatives of patients to enable disease related genotype–phe-
notype correlations to be clearly defined over natural individ-
ual variability as well as from non-related individuals. In
addition, reprogramming vectors may remain integrated in
the patient derived iPS cell line possibly confounding the in-
terpretation of the genotype and phenotype (Saha and
Jaenisch, 2009). This limitation may be overcome by using
viral free reprogramming procedures, currently being devel-
oped in a number of laboratories (Yu et al., 2009; Zhou et
al., 2009; Jia et al., 2010). Given that MS is a chronic disease
most commonly diagnosed in adult life, another consideration
that needs to be addressed is the effect of age on the disease
process and how this is reflected in the iPS cell model.
It appears that epigenetic memory, which may reflect the
patient's age, is not always preserved in these iPS cells and
therefore the addition of substrates to reflect aging or long-
term studies both in vitro and in vivo may be required (Lee
and Studer, 2010). Imprinted genes examined in human ES
and iPS cells has indicated a substantial degree of genomic
imprinting stability, however, a number of cell lines with ab-
normal DNA methylation patterns have been reported (Pick
et al., 2009). This emphasizes the need to examine imprinted
genes for each cell line in order to establish genetic stability,
if such iPS cells are to be used for studying MS.
MS is a complex disease both in etiology as well as patho-
physiology and attempting to model this disease by focusing
on individual differentiated cell types may be seen as an
oversimplification. However, technology in this field is pro-
gressing at an impressive rate and techniques may soon be
available to generate disease relevant phenotypes using
gene therapy, engineered biomaterials and co-cultures that
may provide important new insights into this severely debil-
itating disease. Nonetheless, our ability to generate MSiPS
cell lines, containing the patient's individual genetic suscep-
tibility to MS, has great potential for future detailed experi-
ments into pathogenesis, phenotypes as well as
individualized treatment response and selection.
Materials and methods
A 6 mm skin punch biopsy was obtained from a 35 years old
female with relapsing remitting MS following informed con-
sent. This procedure was carried out under human research
subject and stem cell protocols approved by the institutional
review boards of Monash University and Monash Medical Cen-
tre, Melbourne, Australia.
Preparation of MS patient dermal fibroblasts
The skin biopsy was mechanically dissociated and plated for
dermal fibroblast expansion in DMEM medium supplement
with 10% fetal calf serum, 2 mM L-glutamine, 50 U/ml peni-
cillin, 50 mg/ml streptomycin and 0.25 μg/ml fungizone an-
tibiotic (Invitrogen, Mulgrave, Australia). Fibroblasts
(referred as HDF) grew from the explant after 14 days and
were passaged every 5–7 days or when they achieved 80%
confluence (Park et al., 2008).Retroviral transfection of human fibroblast cells
Vectors containing human OCT3/4, SOX2, KLF4 and c-MYC
were introduced into 293FT cells and the supernatant cul-
tured with HDF cells for 24 h as described previously
(Takahashi et al., 2007; Park et al., 2008). After 6 days, the
transduced HDF cells were re-seeded onto mouse embryonic
fibroblasts (MEF) feeders in knockout (KO) DMEM (Invitrogen,
Mulgrave, Australia) containing 20% KO serum replacement
and human basic FGF (10 ng/ml). On day seven, 0.25 mM bu-
tyrate was added for seven days. Eighteen days after trans-
duction, colonies were mechanically dissociated for re-
plating and are referred to as MSiPS. To test the differentia-
tion capacity of the MSiPS cells after 18 days of culture, float-
ing suspension cultures were used to form EBs as previously
described (Takahashi et al., 2007; Park et al., 2008).
Alkaline phosphatase staining and immunofluores-
cence microscopy
Following 4% paraformaldehyde fixation, alkaline phospha-
tase staining for the phenotypic characterization of MSiPS
cells was assessed using a leukocyte alkaline phosphatase
kit (Sigma-Aldrich, St Louis, MO, USA). Immunofluorescence
for the hES-cell specific proteins TRA-1-60 and TRA-1-81
was performed using an ES cell characterization kit (Milli-
pore, Billerica, MA, USA) and an OCT3/4 primary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Reverse transcription PCR (RT-PCR)
RNA was extracted fromMSiPS cells (passage 5), HDF, EBs (day
18 of differentiation), neurally differentiated MSiPS cells and
hES cell line (H9) (obtained from the Australian Stem Cell Cen-
tre Core Laboratories, Monash University, Australia) using a
Picopure RNA isolation kit (Bio-strategy, New York, NY, USA).
RT-PCR was performed using a SuperScript III first-strand syn-
thesis system (Invitrogen, Mulgrave, Australia) and a platinum
TaqDNA polymerase (Invitrogen, Mulgrave, Australia) accord-
ing to the manufacturer's instructions; relative to a β-actin
housekeeping gene. The primers used in this study are listed
in Table 2 (Takahashi et al., 2007; Park et al., 2008; Zaibak
et al., 2009; Cabras et al., 2010; Jang et al., 2010; Sundberg
et al., 2010; Wang et al., 2010; Ziegler et al., 2011).
PCR of genomic DNA
DNAwas extracted using a DNase blood and Tissue Kit (Qiagen,
CA, USA) and performed as published (Takahashi et al., 2007).
Qualitative PCR (qPCR)
RNA was extracted from HDF, MSiPS cells (passage 5), neu-
rally differentiated MSiPS cells and hES cell line (H9), cDNA
was transcribed using SuperScript III first-strand synthesis
system (Invitrogen,) according to the manufacturer's instruc-
tions. qRT-PCR experiments were performed using a The
LightCycler® 480 Real-Time PCR System (Roche Applied Sci-
ence) with Platinum SYBR Green qPCR superMix-UDG (Invi-
trogen, Mulgrave, Australia) and primers that were specific
Table 2 Primers.
Gene Sense Antisense
OCT3/4 GACAGGGGGAGGGGAGGAGCTAGG CTTCCCTCCAACCAGTTGCCCCAAAC
SOX2 GGGAAATGGGAGGGGTGCAAAAGAGG TTGCGTGAGTGTGGATGGGATTGGTG
KLF4 ACGATCGTGGCCCCGGAAAAGGACC TGATTGTAGTGCTTTCTGGCTGGGCTCC
c-MYC GCGTCCTGGGAAGGGAGATCCGGAGC TTGAGGGGCATCGTCGCGGGAGGCTG
TERT CCTGCTCAAGCTGACTCGACACCGTG GGAAAAGCTGGCCCTGGGGTGGAGC
REX1 CAGATCCTAAACAGCTCGCAGAAT GCGTACGCAAATTAAAGTCCAGA
Nanog CAGCCCCGATTCTTCCACCAGTCCC GGAAGATTCCCAGTCGGGTTCACC
AFP AGCTTGGTGGTGGATGAAAC CCCTCTTCAGCAAAGCAGAC
SMA CTGTTCCAGCCATCCTTCAT CGGCTTCATCGTATTCCTGT
NCAM ATGGAAACTCTATTAAAGTGAACCTG TAGACCTCATACTCAGCATTCCAGT
SOX1 ATGAACGCCTTCATGGTGTGG AGCGAGTACTTGTCCTTCTTG
Pax6 AACAGACACAGCCCTCACAAACA CGGGAACTTGAACTGGAACTGAC
Nestin CAGCTGGCGCACCTCAAGATG AGGGAAGTTGGGCTCAGGACTGG
Tuj1 GAACCCGGAACCATGGACAG GACCCTTGGCCCAGTTGTTG
MAP2 TGCCATCTTGGTGCCGA CTTGACATTACCACCTCCAGGT
S100 AGGGAGACAAGCACAAGCTGAAGA TGTCCACAACCTCCTGCTCTTTGA
GFAP ACCAGGACCTGCTCAATGTC ATCTCCACGGTCTTCACCAC
PLP CCAAATGACCTTCCACCTGT CAGCATTGTAGGCTGTGTGG
NSE CTGATGCTGGAGTTGGATGG CCATTGATCACGTTGAAGGC
Oligo2 CAGAAGCGCTGATGGTCATA TCGGCAGTTTTGGGTTATTC
β-actin CAGAGCCTCGCCTTTGCCG CTCGCGGTTGGCCTTGGG
Nav1.1 CATCCGTGGCTCCCTAT TCATCTGCGAAGTCGTTCT
Nav1.2 CAGAGGGCTTACAGACGC CATACGAGGGTGGAGACG
Nav1.3 TGATGGTGGAAACGGATGA ACTCGGAACAAGGTAGGGG
Nav1.6 GCACCGTTCACTGTATTTGG TGCTTGTTGGATTGGGTTT
Nav1.7 ACACTCTTGGCTACTCAGATC GCATTCACAACGACCCT
β-actin (quantification of Nav expression) CTGGCCGGGACCTGACAGACTACC ATCGGAACCGCTCGTTGCCAATAG
270 B. Song et al.for Nav1.1,Nav1.2 Nav1.3, Nav1.6, Nav1.7. The thermocy-
cling protocol included an initial cycle at 95 °C for 10 min,
followed by 45 cycles of PCR at 95 °C for 15 s, 58 °C for
15 s and 72 °C for 15 s. Each sample was run in experimental
triplicate. The samples were quantification adjusted to the
quantitative expression of β-actin from the same samples.
Bisulfite genomic sequencing
The methylation statuses of cytosine guanine dinucleotides
(CpG) in the promoter region of pluripotent-associated
genes such as OCT3/4 in HDF, MSiPS cell clones and H9
cells were examined using EPi Tect Bisulfite kit Qiagen and
TOPO TA cloning Kit, (Invitrogen, Mulgrave, Australia).
Karyotype
Karyotype analysis was assessed in MSiPS cells at passage 5
and NSCs passage 3 (Southern Cross Pathology, Clayton,
Australia).
Gene expression profiling
Total RNA was extracted from the samples as above. RNA
quality was assessed using a NanoDrop 2000 analyzer (Ther-
mo Scientific). Total RNA from each sample was amplified,
labeled, and hybridized to human HT12v4 BeadChips accord-
ing to Illumina standard protocols (Illumina) at theAustralian Genome Research Facility. Initial data analysis
was performed using GenomeStudio Version 2010.2 (Illu-
mina), using average normalization across all the samples.
For further analysis, data was exported from GenomeStudio
without any normalization and was processed using R/Bio-
Conductor (R Development Core Team, 2010) using algo-
rithms within the lumi package function: bgAdjust.affy (Du
et al., 2008); and quantile normalization (Bolstad et al.,
2003). Subsequent data analysis was performed using Multi-
Experiment Viewer (Saeed et al., 2003).Teratoma assay
Xenografts of undifferentiated MSiPS cells clone 12 (passage
6) were transplanted under the kidney capsule of immune-
compromised NOD-SCID mice (n=3 animals). Teratoma for-
mation was assessed after 8 weeks by hematoxylin and
eosin-stained paraffin sections (Takahashi et al., 2007).Fingerprinting analysis
Short tandem repeats-based (STR) DNA-profiling was used
for fingerprinting analysis to verify the genetic source of
the MSiPS cells to their parent HDF cells. An ABI Prism 3100
DNA sequencer was used with Genescan software (Applied
Biosystems). DNA was extracted using a DNase blood and Tis-
sue Kit (Qiagen, Doncaster, Australia).
271Generation of multiple sclerosis-specific neural cellsNeural differentiation of MSiPS cells
Day 6 MSiPS cell colonies were dissected and each colony
piece was transferred into an ultra low attachment plate
and cultured in suspension for 2 weeks in complete NS medi-
um in order to allow neurosphere formation. The medium
consisted of human NS basal medium and NS proliferation
supplements (NeuroCult, Stem Cell Technologies, Vancou-
ver, BC, Canada), supplemented with 20 ng/ml EGF (Peptro-
tech, Rocky Hill, NJ, USA) and 20 ng/ml human bFGF
(Chemicon, Temecula, CA, USA) and was refreshed every
2 days. Neurospheres were dissociated by disaggregation
with 0.05% trypsin-EDTA (Invitrogen, Mulgrave, Australia).
The dissociated cells were seeded in complete NS medium
onto adherent plates coated with laminin (Invitrogen, Mul-
grave, Australia) to generate a monolayer of neural precur-
sor cells referred to as NSCs. NSCs were passaged with
accutase (Chemicon, Temecula, CA, USA) up to passage 12
with successful freezing and thawing of the cells.
To promote neuronal and astrocyte differentiations, NSCs
were re-plated onto poly-L-ornithine/laminin treated wells
at 2.5×104 cells/cm2 in complete NS medium which con-
sisted of human NS basal media and NS differentiation sup-
plements (NeuroCult, Stem Cell Technologies, Vancouver,
BC, Canada) without growth factors. Medium was changed
every 3–4 days and cells were cultured for 4 weeks.
To allow oligodendrocyte differentiation NSCs were plat-
ed onto poly-L-ornithine/laminin coated wells at
2.5×104 cells/cm2 in neural basal medium that contained
2% B27, 2 mM Glutamax, penicillin (50 U/ml), streptomycin
(50 μg/ml) (Invitrogen, Mulgrave, Australia) and supplemen-
ted with 60 ng/ml T3 (Sigma-Aldrich, St Louis, MO, USA) for
5 weeks. Medium was changed every 2–3 days.Immunofluorescence
Cells plated on cover slips were washed in PBS and fixed with
4% paraformaldehyde for 10 min, washed in PBS and blocked
for 1 h in blocking buffer (10% NGS, 1% BSA). The cells were
incubated with primary antibodies overnight at 4 °C and
then with the appropriate secondary conjugates. 4′,6-diami-
dino-2-pheylindole (DAPI) was used for nuclear counterstain-
ing (Supplementary Information). The following antibodies
were used: rabbit anti-GFAP polyclonal antibody (1:1000),
rabbit anti-MAP2 polyclonal antibody (1:800), mouse anti-
CNPase monoclonal antibody (1:100) (Chemicon, Temecula,
CA, USA), rabbit anti-nestin polyclonal antibody (1:100,
ABcam), mouse anti-βIII-tubulin monoclonal antibody
(1:800, Covance), mouse anti RC2 monoclonal antibody
(1:80, DSHB), mouse IgM anti-A2B5 monoclonal antibody
(1:20) was produced by hybridomas. Mouse anti NF-200
monoclonal antibody (1:200, Invitrogen, Mulgrave, Austra-
lia), mouse anti-O4 monoclonal antibody (1:200, Chemicon,
Temecula, CA, USA), mouse anti-CNPase monoclonal anti-
body (1:100, Chemicon, Temecula, CA, USA), mouse anti-
MOSP monoclonal antibody(1:500, Chemicon, Temecula,
CA, USA), AlexaFluor 568 or 488-conjugated goat anti-
mouse IgG, AlexaFluor568-conjugated goat anti-mouse IgM
(1:1000), AlexaFluor 488, 568 or 647-conjugated goat anti-
rabbit IgG (1:1000) (Invitrogen, Mulgrave, Australia) and rab-
bit anti-doublecortin polyclonal (1:200, Cell Signaling).Rabbit anti-MBP polyclonal antibody (1:400) and MOG
(1:100) polyclonal antibodies were both produced in our lab-
oratory as previously described (Sheng et al., 1988). Isotype-
matched immunoglobulins were used as negative controls
(Invitrogen, Mulgrave, Australia). Cell number of the neural
lineages was determined by counting the number of positive
cells per field at ×40 magnification, using a fluorescent mi-
croscope (Olympus Provis Ax70). Seven to 10 visual fields
were randomly selected and 39 to 846 cells counted for
each samples analyzed. All results are expressed as mean
±SEM.
Image acquisition and analysis
Analysis of immunofluorescence histology was performed
using the 40× (oil) objective lens of an Olympus Provis
Ax70 microscope. The detailed examination of selected
cells was performed using either an Olympus Fluoview
FV1000 confocal microscope (Olympus, GmbH) and FV10-
ASW software (version 1.7.2.2; Olympus) with the images
taken using PLAPO 40× and 60× 02PH NA1.40 objective
lenses or with the NikonC1 confocal microscope with the im-
ages collected by NIS software and image taken using a
PLAPO VC 60X02PH NA1.4 objective lens. Images were ac-
quired in the XY scan mode at 12.5–40 μs/pixel sequentially
using Kalman line integration or in the latter case with FIJI.
Confocal images were saved as gray scale TIFF files. Tiff
files were analyzed using Adobe Photoshop v9.0.2 (Adobe
Systems Incorporated) software with minor brightness and
contrast adjustments performed in a linear manner. Immu-
nofluorescence images were colored and combined to pro-
duce pseudo-colored merged images.
Electrophysiology
Electrophysiological recordings were made using standard
whole-cell patch-clamp techniques and an Axopatch 200 am-
plifier (Axon Instruments Inc, CA, USA). Coverslips contain-
ing cells were placed in a recording chamber (Warner
Instruments, Hamden CT, USA) and continuously superfused
with Hanks physiological saline solution (HPSS) containing
(mM): NaCl 137, NaHCO3 4, NaH2PO4 0.3, KCl 5.4, KH2PO4
0.44, MgCl2 0.5, MgSO4 0.4, glucose 5.6, HEPES 10, CaCl2
1.3, at pH 7.4. Patch electrodes were filled with solution
containing (mM); KCl 135, MgCl2 1.2, ATP 1, EGTA 1, HEPES
10, pH 7.2. Data were digitized at 5–20 kHz with a 1 kHz
low-pass filter, stored on computer and analyzed using
Clampfit 9 (Axon Instruments).
Resting membrane potential and input capacitance and
resistance were recorded in current clamp mode. Depolariz-
ing current steps were used to evoke action potentials. Volt-
age gated inward currents were recorded in voltage clamp
mode using depolarizing steps in 10 mV intervals from a
holding potential of −100 mV. Tetrodotoxin (TTX) was used
to block voltage gated Na+ currents (Sigma-Aldrich).
Statistical analysis
Heatmap for gene expression was generated using ANOVA
with Bonferroni correction to identify genes with significant
(PN0.05) changes between samples. Hierarchical clustering
272 B. Song et al.of genes was performed using Pearson correlation with aver-
age linkage clustering.Acknowledgments
This study was supported by grants from the Eva and Les
Erdi AUSiMED Fellowship in Neurological Diseases, the
Baker Foundation and the NHMRC of Australia. We thank
Drs. Anna Michalska and Antonietta Guidice for initial tech-
nical support and the Departments of Dermatology and Neu-
rology, Monash Medical Center Southern Health, for their
invaluable assistance with patients. Martin Short is sup-
ported by a Clinical Fellowship from Biogen Idec.Appendix A. Supplementary data
Supplementary data to this article can be found online at
doi:10.1016/j.scr.2011.12.001.References
Baranzini, S.E., Jeong, M.C., Butunoi, C., Murray, R.S., Bernard,
C.C., Oksenberg, J.R., 1999. B Cell repertoire diversity and clon-
al expansion in multiple sclerosis brain lesions. J. Immunol. 163,
5133–5144.
Barberi, T., Klivenyi, P., Calingasan, N.Y., Lee, H., Kawamata, H.,
Loonam, K., 2003. Neural subtype specification of fertilization
and nuclear transfer embryonic stem cells and application in par-
kinsonian mice. Nat. Biotechnol. 21, 1200–1207.
Barnett, M.H., Prineas, J.W., 2004. Relapsing and remitting multi-
ple sclerosis: pathology of the newly forming lesion. Ann. Neurol.
55, 458–468.
Ben-Ari, Y., Cherubini, E., Corradetti, R., Gaiarsa, J., 1989. Giant
synaptic potentials in immature rat CA3 hippocampal neurones.
J. Physiol. 416, 303–325.
Bernardinelli, L., Murgia, S.B., Bitti, P.P., Foco, L., Ferrai, R., Musu,
L., Prokopenko, I., Pastorino, R., Saddi, V., Ticca, A., Piras,
M.L., Cox, D.R., Berzuini, C., 2007. Association between the
ACCN1 gene and multiple sclerosis in Central East Sardinia.
PLoS One 2, e480.
Bolstad, B.M., Irizarry, R.A., Astrand, M., Speed, T.P., 2003. A com-
parison of normalization methods for high density oligonucleo-
tide array data based on variance and bias. Bioinformatics 19,
185–193.
Booth, D.R., Arthur, A.T., Teutsch, S.M., Bye, C., Rubio, J., Armati,
P.J., 2005. Gene expression and genotyping studies implicate
the interleukin 7 receptor in the pathogenesis of primary pro-
gressive multiple sclerosis. J. Mol. Med. (Berl) 83, 822–830.
Cabras, S., Saba, F., Reali, C., Scorciapino, M.L., Sirigu, A., Talani,
G., 2010. Antidepressant imipramine induces human astrocytes
to differentiate into cells with neuronal phenotype. Int. J. Neu-
ropsychopharmacol. 13, 603–615.
Chamberlain, S.J., Chen, P.F., Ng, K.Y., Bourgois-Rocha, F., Lem-
tiri-Chlieh, F., Levine, E.S., 2010. Induced pluripotent stem
cell models of the genomic imprinting disorders Angelman and
Prader-Willi syndromes. Proc. Natl. Acad. Sci. U. S. A. 107,
17668–17673.
Cherubini, E., Ben-Ari, Y., 2011. The immature brain needs GABA to
be excited and hyper-excited. J. Physiol. 589, 2655–2656.
Christopherson, K.S., Ullian, E.M., Stokes, C.C., Mullowney, C.E.,
Hell, J.W., Agah, A., 2005. Thrombospondins are astrocyte-
secreted proteins that promote CNS synaptogenesis. Cell 120,
421–433.Du, P., Kibbe, W.A., Lin, S.M., 2008. lumi: a pipeline for processing
Illumina microarray. Bioinformatics 24, 1547–1548.
Dutta, R., Trapp, B.D., 2011. Mechanisms of neuronal dysfunction and
degeneration in multiple sclerosis. Prog. Neurobiol. 93, 1–12.
Ebert, A.D., Yu, J., Rose Jr., F.F., Mattis, V.B., Lorson, C.L., Thom-
son, J.A., 2009. Induced pluripotent stem cells from a spinal
muscular atrophy patient. Nature 457, 277–280.
Friese, M.A., Craner, M.J., Etzensperger, R., Vergo, S., Wemmie,
J.A., Welsh, M.J., 2007. Acid-sensing ion channel-1 contributes
to axonal degeneration in autoimmune inflammation of the cen-
tral nervous system. Nat. Med. 13, 1483–1489.
Fugger, L., Friese, M.A., Bell, J.I., 2009. From genes to function: the
next challenge to understanding multiple sclerosis. Nat. Rev.
Immunol. 9, 408–417.
Hatch, M.N., Nistor, G., Keirstead, H.S., 2009. Derivation of high-
purity oligodendroglial progenitors. Methods Mol. Biol. 549, 59–75.
Holley, J.E., Gveric, D., Newcombe, J., Cuzner, M.L., Gutowski,
N.J., 2003. Astrocyte characterization in the multiple sclerosis
glial scar. Neuropathol. Appl. Neurobiol. 29, 434–444.
Hu, R., Cai, W.Q., Wu, X.G., Yang, Z., 2007. Astrocyte-derived es-
trogen enhances synapse formation and synaptic transmission
between cultured neonatal rat cortical neurons. Neuroscience
144, 1229–1240.
Hu, B.Y., Weick, J.P., Yu, J., Ma, L.X., Zhang, X.Q., Thomson, J.A.,
2010. Neural differentiation of human induced pluripotent stem
cells follows developmental principles but with variable poten-
cy. Proc. Natl. Acad. Sci. U. S. A. 107, 4335–4340.
Jang, S., Cho, H.H., Cho, Y.B., Park, J.S., Jeong, H.S., 2010. Func-
tional neural differentiation of human adipose tissue-derived
stem cells using bFGF and forskolin. BMC Cell Biol. 11, 25.
Jia, F., Wilson, K.D., Sun, N., Gupta, D.M., Huang, M., Li, Z., 2010.
A nonviral minicircle vector for deriving human iPS cells. Nat.
Meth. 7, 197–199.
Johnson, M.A., Weick, J.P., Pearce, R.A., Zhang, S.C., 2007. Func-
tional neural development from human embryonic stem cells:
accelerated synaptic activity via astrocyte coculture. J. Neu-
rosci. 27, 3069–3077.
Killestein, J., Polman, C.H., 2011. Determinants of interferon β ef-
ficacy in patients with multiple sclerosis. Nat. Rev. Neurol. 7,
221–228.
Kim, J.E., O'Sullivan, M.L., Sanchez, C.A., Hwang, M., Israel, M.A.,
Brennand, K., 2011. Investigating synapse formation and func-
tion using human pluripotent stem cell-derived neurons. Proc.
Natl. Acad. Sci. U. S. A. 108, 3005–3010.
Krishnan, A.V., Lin, C.S., Park, S.B., Kiernan, M.C., 2009. Axonal ion
channels from bench to bedside: a translational neuroscience
perspective. Prog. Neurobiol. 89, 288–313.
Lassmann, H., 2010. What drives disease in multiple sclerosis: inflam-
mation or neurodegeneration? Clin. Exp. Neuroimmunol. 1, 2–11.
Lee, G., Studer, L., 2010. Induced pluripotent stem cell technology
for the study of human disease. Nat. Meth. 7, 25–27.
Lee, G., Papapetrou, E.P., Kim, H., Chambers, S.M., Tomishima,
M.J., Fasano, C.A., 2009. Modelling pathogenesis and treatment
of familial dysautonomia using patient-specific iPSCs. Nature
461, 402–406.
Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez,
M., Lassmann, H., 2000. Heterogeneity of multiple sclerosis le-
sions: implications for the pathogenesis of demyelination. Ann.
Neurol. 47, 707–717.
Menon, K.N., Steer, D.L., Short, M., Petratos, S., Smith, I., Bernard,
C.C., 2011. A novel unbiased proteomic approach to detect the
reactivity of cerebrospinal fluid in neurological diseases. Mol.
Cell. Proteomics 10 (M110.000042).
Nishikawa, S., Goldstein, R.A., Nierras, C.R., 2008. The promise of
human induced pluripotent stem cells for research and therapy.
Nat. Rev. Mol. Cell Biol. 9, 725–729.
Oksenberg, J.R., Baranzini, S.E., 2010. Multiple sclerosis genetics —
is the glass half full, or half empty? Nat. Rev. Neurol. 6, 429–437.
273Generation of multiple sclerosis-specific neural cellsOnorati, M., Camnasio, S., Binetti, M., Jung, C.B., Moretti, A.,
Cattaneo, E., 2010. Neuropotent self-renewing neural stem
(NS) cells derived from mouse induced pluripotent stem (iPS)
cells. Mol. Cell. Neurosci. 43, 287–295.
Osafune, K., Caron, L., Borowiak, M., Martinez, R.J., Fitz-Gerald,
C.S., Sato, Y., 2008. Marked differences in differentiation propen-
sity among human embryonic stem cell lines. Nat. Biotechnol. 26,
313–315.
Park, I.H., Zhao, R., West, J.A., Yabuuchi, A., Huo, H., Ince, T.A.,
2008. Reprogramming of human somatic cells to pluripotency
with defined factors. Nature 451, 141–146.
Pick, M., Stelzer, Y., Bar-Nur, O., Mayshar, Y., Eden, A., Benvenisty,
N., 2009. Clone- and gene-specific aberrations of parental imprint-
ing in human induced pluripotent stem cells. Stem Cells 27,
2686–2690.
R Development Core Team, 2010. R. A Language and Environment
for Statistical Computing. R Foundation for Statistical Comput-
ing, Vienna, Austria.
Richards, M., Tan, S.P., Tan, J.H., Chan, W.K., Bongso, A., 2004.
The transcriptome profile of human embryonic stem cells as de-
fined by SAGE. Stem Cells 22, 51–64.
Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N.,
2003. TM4: a free, open-source system for microarray data man-
agement and analysis. Biotechniques 34, 374–378.
Saha, K., Jaenisch, R., 2009. Technical challenges in using human in-
duced pluripotent stem cells to model disease. Cell Stem Cell 5,
584–595.
Sharma, R., Fischer, M.T., Bauer, J., Felts, P.A., Smith, K.J., Misu,
T., 2010. Inflammation induced by innate immunity in the cen-
tral nervous system leads to primary astrocyte dysfunction fol-
lowed by demyelination. Acta Neuropathol. 120, 223–236.
Sheng, H.Z., Martenson, R.E., Grgacic, E.V., Dowse, C.A., Carnegie,
R.L., Bernard, C.C.A., 1988. Electroimmunoblotting of myelin
basic protein peptides: a novel approach to rapid characterisa-
tion of antigenic specificties of monoclonal and polyclonal anti-
MBP antibodies. J. Neuroimmunol. 17, 183–192.
Song, B., Niclis, J.C., Alikhan, M.A., Sakkal, S., Sylvain, A., Kerr, P.G.,
2011. Generation of induced pluripotent stem cells from human
kidney mesangial cells. J. Am. Soc. Nephrol. 22, 1213–1220.
Stroh, A., Tsai, H.C., Wang, L.P., Zhang, F., Kressel, J., Aravanis,
A., 2011. Tracking stem cell differentiation in the setting of au-
tomated optogenetic stimulation. Stem Cells 29, 78–88.Su, K.G., Banker, G., Bourdette, D., Forte, M., 2009. Axonal degen-
eration in multiple sclerosis: the mitochondrial hypothesis. Curr.
Neurol. Neurosci. Rep. 9, 411–417.
Sundberg, M., Skottman, H., Suuronen, R., Narkilahti, S., 2010. Pro-
duction and isolation of NG2+ oligodendrocyte precursors from
human embryonic stem cells in defined serum-free medium.
Stem Cell Res. 5, 91–103.
Takahashi, K., Yamanaka, S., 2006. Induction of pluripotent stem
cells from mouse embryonic and adult fibroblast cultures by de-
fined factors. Cell 126, 663–676.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T.,
Tomoda, K., 2007. Induction of pluripotent stem cells from
adult human fibroblasts by defined factors. Cell 131, 861–872.
Wang, L., Wang, Z.H., Shen, C.Y., You, M.L., Xiao, J.F., Chen, G.Q.,
2010. Differentiation of human bone marrow mesenchymal stem
cells grown in terpolyesters of 3-hydroxyalkanoates scaffolds
into nerve cells. Biomaterials 31, 1691–1698.
Waxman, S.G., 2006a. Ions, energy and axonal injury: towards a mo-
lecular neurology of multiple sclerosis. Trends Mol. Med. 12,
192–195.
Waxman, S.G., 2006b. Axonal conduction and injury in multiple
sclerosis: the role of sodium channels. Nat. Rev. Neurosci. 7,
932–941.
Wekerle, H., 2008. Lessons from multiple sclerosis: models, con-
cepts, observations. Ann. Rheum. Dis. 67 (Suppl. 3), iii56–iii60.
Yazawa, M., Hsueh, B., Jia, X., Pasca, A.M., Bernstein, J.A., Hall-
mayer, J., 2011. Using induced pluripotent stem cells to investi-
gate cardiac phenotypes in Timothy syndrome. Nature 471,
230–234.
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I.I.,
2009. Human induced pluripotent stem cells free of vector and
transgene sequences. Science 324, 797–801.
Zaibak, F., Bello, P., Kozlovski, J., Crombie, D., Ang, H., Dottori,
M., 2009. Unrestricted somatic stem cells from human umbilical
cord blood grow in serum-free medium as spheres. BMC Biotech-
nol. 9, 101.
Zhou, H., Wu, S., Joo, J.Y., Zhu, S., Han, D.W., Lin, T., 2009. Gen-
eration of induced pluripotent stem cells using recombinant pro-
teins. Cell Stem Cell 4, 381–384.
Ziegler, L., Grigoryan, S., Yang, I.H., Thakor, N.V., Goldstein, R.S.,
2011. Efficient generation of schwann cells from human embry-
onic stem cell-derived neurospheres. Stem Cell Rev. 7, 394–403.
